高迁移率族蛋白B1及晚期糖基化终产物受体在卵巢癌组织中表达及临床相关性研究

Expression of HMGB1 and RAGE in human ovarian carcinoma and their biological significances

目的分析高迁移率族蛋白B1(HMGB1)及晚期糖基化终产物受体(RAGE)蛋白在卵巢癌组织中的表达及其与临床病理相关因素的关系。方法选取2010—2015年齐齐哈尔市第一医院和齐齐哈尔医学院附属医院卵巢癌标本存档蜡块45例为A组,卵巢良性肿瘤标本存档蜡块37例为B组。采用免疫组织化学技术检测两组HMGB1和RAGE的表达情况,分析其表达与卵巢癌组织的病理分级、临床分期、淋巴结转移等临床病理因素的关系。结果 HMGB1及RAGE在A组中的阳性表达率分别为77.8%(35/45)和71.1%(32/45);在B组中的阳性表达率分别为10.8%(4/37)和16.2%(6/37);组间比较,差异均有统计学意义(P<0.05)。卵巢癌病理分级、淋巴结转移与HMGB1及RAGE高表达有密切关系(P<0.05);HMGB1与RAGE基因表达呈正相关(P<0.05)。结论 HMGB1和RAGE基因表达与卵巢癌临床病理学特征密切相关,HMGB1/RAGE信号通路可能参与卵巢癌的转移,可作为临床卵巢癌药物治疗的重要候选靶点。

Objective To study the expression of high mobility group box-1 protein（ HMGB1） and advanced glycation end product receptor（ RAGE） in human ovarian carcinoma to investigate the relationship between the expression levels and lymphatic metastasis.Methods A retrospective study was performed on specimens from 2010 to 2015. The 45 cases of specimens which were taken from ovarian carcinoma tissue were in Group A and the other 37 cases which were taken from normal ovarian tissue were in Group B. Expression of HMGB1 and RAGE were examined by immunohistochemistry,the relationship between gene expression and the histological grade of ovarian cancer tissue,clinical stage,lymph node metastasis were analyzed. Results The positive expression of HMGB1 and RAGE protein in Group A was 77. 8%（ 35/45） and 71. 1%（ 32/45）,respectively; in Group B was 10. 8%（ 4/37） and 16. 2%（ 6/37）,respectively; the difference between the two groups was statistically significant（ P〈0. 05）. The expression rate of HMGB1 and RAGE protein were closely correlated with the histological grade and lymph node metastasis in ovarian carcinoma（ P〈0. 05）; the positive expression rate of HMGB1 was positively correlated with RAGE（ P〈0. 05）. Conclusion HMGB1 and RAGE gene expression are closely related to the clinical pathology of ovarian cancer,and HMGB1/RAGE signaling pathway may participate in the metastasis of ovarian cancer,which can be a key candidate target for clinical ovarian cancer drug therapy.